{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:28:23Z","timestamp":1773980903328,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>To assess whether a\u00a0single training session for general practitioners (GPs) improves the evidence-based drug treatment of heart failure (HF) patients, especially of those with HF with reduced ejection fraction (HFrEF).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>A\u00a0cluster randomised controlled trial was performed for which patients with established HF were eligible. Primary care practices (PCPs) were randomised to care-as-usual or to the intervention group in which GPs received a\u00a0half-day training session on HF management. Changes in HF medication, health status, hospitalisation and survival were compared between the two groups. Fifteen PCPs with 200 HF patients were randomised to the intervention group and 15\u00a0PCPs with 198 HF patients to the control group. Mean age was 76.9 (SD 10.8) years; 52.5% were female. On average, the patients had been diagnosed with HF 3.0 (SD 3.0) years previously. In total, 204 had HFrEF and 194 HF with preserved ejection fraction (HFpEF). In participants with HFrEF, the use of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers decreased in 6\u00a0months in both groups [5.2%; (95% confidence interval (CI) 2.0\u201310.0)] and 5.6% (95% CI 2.8\u201313.4)], respectively [baseline-corrected odds ratio (OR) 1.07 (95% CI 0.55\u20132.08)], while beta-blocker use increased in both groups by 5.2% (95% CI 2.0\u201310.0) and 1.1% (95% CI 0.2\u20136.3), respectively [baseline-corrected OR 0.82 (95% CI 0.42\u20131.61)]. For health status, hospitalisations or survival after 12\u201328\u00a0months there were no significant differences between the two groups, also not when separately analysed for HFrEF and HFpEF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A\u00a0half-day training session for GPs does not improve drug treatment of HF in patients with established HF.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12471-020-01487-x","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T11:04:13Z","timestamp":1601463853000},"page":"604-612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Training general practitioners to improve evidence-based drug treatment of patients with heart failure: a\u00a0cluster randomised controlled trial"],"prefix":"10.1007","volume":"28","author":[{"given":"M. J. M.","family":"Valk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. W.","family":"Hoes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mosterd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Landman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. P. A.","family":"Zuithoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. D. L.","family":"Broekhuizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. H.","family":"Rutten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"issue":"8","key":"1487_CR1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski\u00a0P, Voors\u00a0AA, Anker\u00a0SD, Bueno\u00a0H, Cleland\u00a0JG, Coats\u00a0AJ, et\u00a0al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891\u2013975.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1487_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/ehjcvp\/pvu010","volume":"1","author":"J de Blois","year":"2015","unstructured":"de Blois\u00a0J, Fagerland\u00a0MW, Grundtvig\u00a0M, Semb\u00a0AG, Gullestad\u00a0L, Westheim, et\u00a0al. ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry. Eur Heart J Cardiovasc Pharmacother. 2015;1(1):31\u20136.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"8","key":"1487_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","volume":"14","author":"JJ McMurray","year":"2012","unstructured":"McMurray\u00a0JJ, Adamopoulos\u00a0S, Anker\u00a0SD, Auricchio\u00a0A, Bohm\u00a0M, Dickstein\u00a0K, et\u00a0al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012of;14(8):803\u201369.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"1487_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jacc.2009.06.067","volume":"55","author":"WJ Paulus","year":"2010","unstructured":"Paulus\u00a0WJ, van Ballegoij\u00a0JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J\u00a0Am Coll Cardiol. 2010;55(6):526\u201337.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"1487_CR5","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.2014.15241","volume":"312","author":"LH Lund","year":"2014","unstructured":"Lund\u00a0LH, Benson\u00a0L, Dahlstrom\u00a0U, Edner\u00a0M, Friberg\u00a0L. Association between use of beta-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA. 2014;312(19):2008\u201318.","journal-title":"JAMA"},{"issue":"40","key":"1487_CR6","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/eurheartj\/ehu204","volume":"35","author":"M Senni","year":"2014","unstructured":"Senni\u00a0M, Paulus\u00a0WJ, Gavazzi\u00a0A, Fraser\u00a0AG, Diez\u00a0J, Solomon\u00a0SD, et\u00a0al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart\u00a0J. 2014;35(40):2797\u2013815.","journal-title":"Eur Heart J"},{"issue":"2","key":"1487_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10741-006-9481-0","volume":"11","author":"C Fonseca","year":"2006","unstructured":"Fonseca\u00a0C. Diagnosis of heart failure in primary care. Heart Fail Rev. 2006;11(2):95\u2013107.","journal-title":"Heart Fail Rev"},{"key":"1487_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2296-7-40","volume":"7","author":"FJ Bongers","year":"2006","unstructured":"Bongers\u00a0FJ, Schellevis\u00a0FG, Bakx\u00a0C, van den Bosch\u00a0WJ, van der Zee\u00a0J. Treatment of heart failure in Dutch general practice. BMC Fam Pract. 2006;7:40.","journal-title":"BMC Fam Pract"},{"key":"1487_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1388-9842(03)00050-3","volume":"5","author":"FH Rutten","year":"2003","unstructured":"Rutten\u00a0FH, Grobbee\u00a0DE, Hoes\u00a0AW. Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a\u00a0survey in every-day practice. Eur J Heart Fail. 2003;5:337\u201344.","journal-title":"Eur J Heart Fail"},{"issue":"649","key":"1487_CR10","doi-asserted-by":"publisher","first-page":"e587","DOI":"10.3399\/bjgp16X685705","volume":"66","author":"MJ Valk","year":"2016","unstructured":"Valk\u00a0MJ, Mosterd\u00a0A, Broekhuizen\u00a0BD, Zuithoff\u00a0NP, Landman\u00a0MA, Hoes\u00a0AW, et al. Overdiagnosis of heart failure in primary care: a\u00a0cross-sectional study. Br J Gen Pract. 2016;66(649):e587\u2013e92.","journal-title":"Br J Gen Pract"},{"key":"1487_CR11","doi-asserted-by":"publisher","first-page":"f4403","DOI":"10.1136\/bmj.f4403","volume":"347","author":"S Gjelstad","year":"2013","unstructured":"Gjelstad\u00a0S, Hoye\u00a0S, Straand\u00a0J, Brekke\u00a0M, Dalen\u00a0I, Lindbaek\u00a0M. Improving antibiotic prescribing in acute respiratory tract infections: cluster randomised trial from Norwegian general practice (prescription peer academic detailing (Rx-PAD) study). BMJ. 2013;347:f4403.","journal-title":"BMJ"},{"issue":"3","key":"1487_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/pds.1243","volume":"16","author":"FE Horn","year":"2007","unstructured":"Horn\u00a0FE, Mandryk\u00a0JA, Mackson\u00a0JM, Wutzke\u00a0SE, Weekes\u00a0LM, Hyndman\u00a0RJ. Measurement of changes in antihypertensive drug utilisation following primary care educational interventions. Pharmacoepidemiol Drug Saf. 2007;16(3):297\u2013308.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"1487_CR13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","volume":"10","author":"K Dickstein","year":"2008","unstructured":"Dickstein\u00a0K, Cohen-Solal\u00a0A, Filippatos\u00a0G, McMurray\u00a0JJ, Ponikowski\u00a0P, Poole-Wilson\u00a0PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008of;10(10):933\u201389.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1487_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12875-015-0347-1","volume":"16","author":"MJ Valk","year":"2015","unstructured":"Valk\u00a0MJ, Hoes\u00a0AW, Mosterd\u00a0A, Landman\u00a0MA, Broekhuizen\u00a0BD, Rutten\u00a0FH. Rationale, design and baseline results of the Treatment Optimisation in Primary care of Heart failure in the Utrecht region (TOPHU) study: a\u00a0cluster randomised controlled trial. BMC Fam Pract. 2015;16(1):130.","journal-title":"BMC Fam Pract"},{"issue":"2","key":"1487_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/fampra\/cmn105","volume":"26","author":"MJ Calvert","year":"2009","unstructured":"Calvert\u00a0MJ, Shankar\u00a0A, McManus\u00a0RJ, Ryan\u00a0R, Freemantle\u00a0N. Evaluation of the management of heart failure in primary care. Fam Pract. 2009;26(2):145\u201353.","journal-title":"Fam Pract"},{"issue":"6","key":"1487_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S0300-8932(10)70160-3","volume":"63","author":"SM Anguita","year":"2010","unstructured":"Anguita\u00a0SM, Jimenez-Navarro\u00a0M, Crespo\u00a0M, Alonso-Pulpon\u00a0L, de Teresa\u00a0E, Castro-Beiras\u00a0A, et al. Effect of a\u00a0training program for primary care physicians on the optimization of beta-blocker treatment in elderly patients with heart failure. Rev Esp Cardiol. 2010;63(6):677\u201385.","journal-title":"Rev Esp Cardiol"},{"issue":"2","key":"1487_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1475-6773.2005.0l374.x","volume":"40","author":"KW Wyrwich","year":"2005","unstructured":"Wyrwich\u00a0KW, Tierney\u00a0WM, Babu\u00a0AN, Kroenke\u00a0K, Wolinsky\u00a0FD. A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv Res. 2005;40(2):577\u201391.","journal-title":"Health Serv Res"},{"issue":"1","key":"1487_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","volume":"7","author":"HP Brunner-La Rocca","year":"2019","unstructured":"Brunner-La Rocca\u00a0HP, Linssen\u00a0GC, Smeele\u00a0FJ, van Drimmelen\u00a0AA, Schaafsma\u00a0HJ, Westendorp\u00a0PH, et al. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF Registry. JACC Heart Fail. 2019;7(1):13\u201321. https:\/\/doi.org\/10.1016\/j.jchf.2018.10.010.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"1487_CR19","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/ejhf.173","volume":"16","author":"ML Luttik","year":"2014","unstructured":"Luttik\u00a0ML, Jaarsma\u00a0T, van Geel\u00a0PP, Brons\u00a0M, Hillege\u00a0HL, Hoes\u00a0AW, et al. Long-term follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH\u20112 study. Eur J Heart Fail. 2014;16(11):1241\u20138.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"1487_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/eurheartj\/ehs235","volume":"34","author":"M Schou","year":"2013","unstructured":"Schou\u00a0M, Gustafsson\u00a0F, Videbaek\u00a0L, Tuxen\u00a0C, Keller\u00a0N, Handberg\u00a0J, et al. Extended heart failure clinic follow-up in low-risk patients: a\u00a0randomized clinical trial (NorthStar). Eur Heart\u00a0J. 2013;34(6):432\u201342.","journal-title":"Eur Heart J"},{"issue":"1","key":"1487_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ahj.2003.07.022","volume":"147","author":"R Gupta","year":"2004","unstructured":"Gupta\u00a0R, Tang\u00a0WH, Young\u00a0JB. Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a\u00a0specialized outpatient heart failure clinic. Am Heart\u00a0J. 2004;147(1):79\u201383.","journal-title":"Am Heart J"},{"issue":"5","key":"1487_CR22","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/j.1365-2753.2008.01060.x","volume":"14","author":"F Peters-Klimm","year":"2008","unstructured":"Peters-Klimm\u00a0F, Muller-Tasch\u00a0T, Remppis\u00a0A, Szecsenyi\u00a0J, Schellberg\u00a0D. Improved guideline adherence to pharmacotherapy of chronic systolic heart failure in general practice\u2014results from a\u00a0cluster-randomized controlled trial of implementation of a\u00a0clinical practice guideline. J\u00a0Eval Clin Pract. 2008;14(5):823\u20139.","journal-title":"J Eval Clin Pract"},{"issue":"15","key":"1487_CR23","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt\u00a0B, Pfeffer\u00a0MA, Assmann\u00a0SF, Boineau\u00a0R, Anand\u00a0IS, Claggett\u00a0B, et\u00a0al. Spironolactone for heart failure with preserved ejection fraction. N\u00a0Engl J Med. 2014;370(15):1383\u201392.","journal-title":"N Engl J Med"},{"issue":"17","key":"1487_CR24","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"S de Denus","year":"2017","unstructured":"de Denus\u00a0S, O\u2019Meara\u00a0E, Desai\u00a0AS, Claggett\u00a0B, Lewis\u00a0EF, Leclair\u00a0G, et\u00a0al. Spironolactone metabolites in TOPCAT\u2014new insights into regional variation. N\u00a0Engl J Med. 2017;376(17):1690\u20132.","journal-title":"N Engl J Med"},{"issue":"2","key":"1487_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1176\/appi.psy.48.2.112","volume":"48","author":"N Holzapfel","year":"2007","unstructured":"Holzapfel\u00a0N, Zugck\u00a0C, Muller-Tasch\u00a0T, Lowe\u00a0B, Wild\u00a0B, Schellberg\u00a0D, et al. Routine screening for depression and quality of life in outpatients with congestive heart failure. Psychosomatics. 2007;48(2):112\u20136.","journal-title":"Psychosomatics"},{"issue":"3","key":"1487_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/heart.87.3.235","volume":"87","author":"J Juenger","year":"2002","unstructured":"Juenger\u00a0J, Schellberg\u00a0D, Kraemer\u00a0S, Haunstetter\u00a0A, Zugck\u00a0C, Herzog\u00a0W, et\u00a0al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart. 2002;87(3):235\u201341.","journal-title":"Heart"},{"issue":"4","key":"1487_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejim.2013.01.003","volume":"24","author":"M Scherer","year":"2013","unstructured":"Scherer\u00a0M, Dungen\u00a0HD, Inkrot\u00a0S, Tahirovic\u00a0E, Lashki\u00a0DJ, Apostolovic\u00a0S, et al. Determinants of change in quality of life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD). Eur J Intern Med. 2013;24(4):333\u20138.","journal-title":"Eur J Intern Med"},{"issue":"11","key":"1487_CR28","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0895-4356(98)00097-3","volume":"51","author":"NK Aaronson","year":"1998","unstructured":"Aaronson\u00a0NK, Muller\u00a0M, Cohen\u00a0PD, Essink-Bot\u00a0ML, Fekkes\u00a0M, Sanderman\u00a0R, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J\u00a0Clin Epidemiol. 1998;51(11):1055\u201368.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1487_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ageing\/26.1.7","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson\u00a0C, Jenkinson\u00a0D, Shepperd\u00a0S, Layte\u00a0R, Petersen\u00a0S. Evaluation of treatment for congestive heart failure in patients aged 60 years and older using generic measures of health status (SF-36 and COOP charts). Age Ageing. 1997;26(1):7\u201313.","journal-title":"Age Ageing"},{"issue":"2","key":"1487_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5694\/j.1326-5377.1997.tb138782.x","volume":"167","author":"FM Blyth","year":"1997","unstructured":"Blyth\u00a0FM, Lazarus\u00a0R, Ross\u00a0D, Price\u00a0M, Cheuk\u00a0G, Leeder\u00a0SR. Burden and outcomes of hospitalisation for congestive heart failure. Med J Aust. 1997;167(2):67\u201370.","journal-title":"Med J Aust"},{"issue":"4","key":"1487_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3109\/13814788.2010.527938","volume":"16","author":"A Andryukhin","year":"2010","unstructured":"Andryukhin\u00a0A, Frolova\u00a0E, Vaes\u00a0B, Degryse\u00a0J. The impact of a\u00a0nurse-led care programme on events and physical and psychosocial parameters in patients with heart failure with preserved ejection fraction: a\u00a0randomized clinical trial in primary care in Russia. Eur J Gen Pract. 2010;16(4):205\u201314.","journal-title":"Eur J Gen Pract"},{"issue":"7","key":"1487_CR32","first-page":"368","volume":"53","author":"AW Hoes","year":"2010","unstructured":"Hoes\u00a0AW, Voors\u00a0AA, Rutten\u00a0FH, Van Lieshout\u00a0J, Janssen\u00a0PGH, Walma\u00a0EP. The Dutch GP guidelines on heart failure (in Dutch: NHG-Standaard Hartfalen, Tweede herziening). Huisarts Wet. 2010;53(7):368\u201389.","journal-title":"Huisarts Wet"},{"key":"1487_CR33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1756-0500-4-212","volume":"4","author":"A Boaz","year":"2011","unstructured":"Boaz\u00a0A, Baeza\u00a0J, Fraser\u00a0A. Effective implementation of research into practice: an overview of systematic reviews of the health literature. BMC Res Notes. 2011;4:212.","journal-title":"BMC Res Notes"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-020-01487-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-020-01487-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-020-01487-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T01:33:24Z","timestamp":1632965604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-020-01487-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1487"],"URL":"https:\/\/doi.org\/10.1007\/s12471-020-01487-x","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"assertion":[{"value":"30 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.J.M.\u00a0Valk, A.W.\u00a0Hoes, A.\u00a0Mosterd, M.A.\u00a0Landman, N.P.A.\u00a0Zuithoff, B.D.L.\u00a0Broekhuizen and F.H.\u00a0Rutten declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}